Structure via PubChem · Public domain (PubChem)
sorafenib
Sign in to saveAlso known as BAY 43-9006, Nexavar®, N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide, sorafenibum, Sorafenibum, N-(4-Chloro-3-(trifluoromethyl)phenyl)-n'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea
Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
Key facts
- Drug.ChEMBL
- 1336
- Drug.PDB_ligand
- BAX
- Drug.verifiedrevid
- 464405524
- Drug.image
- Sorafenib2DACS.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 300
- Drug.image2
- Sorafenib 3D 3gcs.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 250
- Drug.tradename
- Nexavar, others
- Drug.MedlinePlus
- a607051
- Drug.DailyMedID
- Sorafenib
- Drug.licence_EU
- yes
- Drug.licence_US
- Sorafenib
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- EX02
via Wikipedia infobox
Chemical data
- Formula
- C21H16ClF3N4O3
- Molecular weight
- 464.8 g/mol
- IUPAC name
- 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
- SMILES
- CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
- InChIKey
- MLDQJTXFUGDVEO-UHFFFAOYSA-N
- XLogP
- 4.1
- Polar surface area
- 92.4 Ų
- H-bond donors
- 3
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Research
14,346 papers- Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.Theranostics · 2021
- Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1α/SLC7A11 pathway.Cell proliferation · 2022
- Sorafenib.Current opinion in oncology · 2006
- SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.Cell death & disease · 2023
- Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus: A Randomized Clinical Trial.JAMA surgery · 2024
via PubMed
~7 min read
Encyclopedic overview
21 sectionsContents
- Mechanism of action
- Medical uses
- Kidney cancer
- Liver cancer
- Thyroid cancer
- Acute Myeloid Leukaemia
- Adverse effects
- History
- Renal cancer
- Liver cancer
- Society and culture
- Nexavar controversy
- Research
- Lung
- Ovarian cancer
- Brain (recurrent glioblastoma)
- Desmoid tumor (aggressive fibromatosis)
- See also
- Notes
- References
- External links
Sorafenib, sold under the brand name Nexavar, is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
==Mechanism of action== Sorafenib is a protein kinase inhibitor with activity against many protein kinases, including VEGFR, PDGFR and RAF kinases. Of the RAF kinases, sorafenib is more selective for c-Raf than B-RAF. (See BRAF (gene)#Sorafenib for details the drug's interaction with B-Raf.)
Excerpted from Wikipedia’s “sorafenib” article, available under the CC BY-SA 4.0 licence.